3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-trifluoromethylquinolin-4-yl-sulfanyl)pyrrole-2,5-dione | 905854-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-trifluoromethylquinolin-4-yl-sulfanyl)pyrrole-2,5-dione
• 英文别名: 3-(5,6-Dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-trifluoromethyl-quinolin-4-yl-sulfanyl)-pyrrole-2,5-dione；3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-[2-(trifluoromethyl)quinolin-4-yl]sulfanylpyrrole-2,5-dione
• CAS: 905854-25-3
• 化学式: C₂₅H₁₆F₃N₃O₂S
• 分子量: 479.482
• InChiKey: XREMXGSSBLJWJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  89.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  马来酰亚胺 、 2-[[2-(Trifluoromethyl)-4-quinolinyl]thio]acetamide 生成 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-trifluoromethylquinolin-4-yl-sulfanyl)pyrrole-2,5-dione
  参考文献：
  名称：

  Compositions and methods for treatment of cancer

  摘要：

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物以及制备这些化合物的方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物的药物组合物。本发明提供了通过向需要治疗细胞增生性疾病，如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯啉-2,5-二酮化合物的治疗有效量的方法。

  公开号：

  US07713969B2

文献信息

• COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20150328208A1

  公开（公告）日：2015-11-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。
• Compositions and Methods for Treatment of Cancer
  申请人：Li Chiang J.

  公开号：US20100221251A1

  公开（公告）日：2010-09-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物及其制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的制药组合物。本发明提供了通过向需要治疗细胞增殖性疾病，例如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物的治疗有效量的方法。
• MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：EP1846406A1

  公开（公告）日：2007-10-24
• Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer
  申请人：ArQule, Inc.

  公开号：EP2289892B1

  公开（公告）日：2012-08-22
• A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
  申请人：ArQule, Inc.

  公开号：EP2396003B1

  公开（公告）日：2013-04-17